MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4500
0.0000
0.00%
Pre Market: 0.4410 -0.009 -2.00% 04:59 07/06 EDT
OPEN
0.4940
PREV CLOSE
0.4500
HIGH
0.4940
LOW
0.4500
VOLUME
3.28K
TURNOVER
--
52 WEEK HIGH
6.43
52 WEEK LOW
0.3467
MARKET CAP
5.70M
P/E (TTM)
-0.2692
1D
5D
1M
3M
1Y
5Y
Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Kiora Pharmaceuticals (NASDAQ:KPRX) <a href="https://...
Seekingalpha · 17h ago
Kiora Commences Mid-Stage Rare Eye Disease Study
Kiora Pharmaceuticals (NASDAQ: KPRX) enrols the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED).
Benzinga · 18h ago
Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Pe...
Newsfile · 23h ago
Kiora stock rises as vision restoring therapy's trial gets clearance to begin in Australia
Kiora Pharmaceuticals (NASDAQ:KPRX) said it received approval in Australia to begin a first-in-human trial of KIO-301 aimed at restoring lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye
Seekingalpha · 06/27 11:44
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
Salt Lake City, Utah--(Newsfile Corp. - June 27, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients w...
Newsfile · 06/27 10:53
BRIEF-Kiora Pharmaceuticals Inc - Effective As Of June 16, 2022, Drexler Resigned As Interim Chief Financial Officer Of Company
BRIEF-Kiora Pharmaceuticals Inc - Effective As Of June 16, 2022, Drexler Resigned As Interim Chief Financial Officer Of Company
Reuters · 06/21 22:25
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday.
Benzinga · 06/09 10:13
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.
Benzinga · 06/08 16:29
More
No Data
Learn about the latest financial forecast of KPRX. Analyze the recent business situations of KIORA PHARMACEUTICALS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KPRX stock price target is 7.13 with a high estimate of 15.00 and a low estimate of 1.000.
High15.00
Average7.13
Low1.000
Current 0.4500
EPS
Actual
Estimate
-0.53-0.40-0.26-0.13
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 27
Institutional Holdings: 845.84K
% Owned: 6.68%
Shares Outstanding: 12.66M
TypeInstitutionsShares
Increased
3
16.12K
New
5
137.02K
Decreased
3
95.30K
Sold Out
2
31.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.28%
Pharmaceuticals & Medical Research
+0.40%
Key Executives
Chairman/Executive Director
Paul Chaney
President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Brian Strem
Executive Vice President
Franz Obermayr
Other
Eric Daniels
Independent Director
Kenneth Gayron
Independent Director
David Hollander
Independent Director
Erin Parsons
Independent Director
Aron Shapiro
Independent Director
Praveen Tyle
No Data
No Data
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Its wholly owned subsidiaries include Jade Therapeutics, Inc., Kiora Pharmaceuticals, GmbH, Bayon Therapeutics, Inc. and Kiora Pharmaceuticals Pty Ltd.

Webull offers kinds of Kiora Pharmaceuticals Inc stock information, including NASDAQ:KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.